The Value of 18F-FDG PET/CT Technology in Evaluating the Effect of T2DM on the Efficacy of PD-L1 Targeted Therapy in Patients with Advanced Colorectal Cancer

doi:10.7517/issn.1674-0475.210831

Abstract

Abstract: This study explored the evaluation of ¹⁸F-fluorodeoxyglucose positron emission computed tomography/computed tomography (¹⁸F-FDG PET/CT) technology for the evaluation of type 2 diabetes (T2DM) on the programmed death receptor-1 ligand in patients with advanced colorectal cancer (PD-L1) The effect of treatment efficacy. A total of 104 patients with advanced colorectal cancer were selected, and they were divided into T2DM group (n=49) and no T2DM group (n=55) according to whether they were accompanied by T2DM. The efficacy and ¹⁸F-FDG PET/CT technical parameters:average standard uptake value (SUV_mean), maximum standard uptake value (SUV_max), metabolic volume (MTV), total glycolysis of lesions (TLG) were 237 compared between the two groups, and the application value of ¹⁸F-FDG PET/CT were explored. The results showed that the pathological staging, curative effect, SUV_mean, SUV_max, MTV, TLG of the T2DM group were compared with those without T2DM, and the difference was statistically significant (P<0.05); T2DM and T2DM without remission were SUV_mean, SUV_max, MTV, TLG SUVmean, SUV_max, MTV, and TLG in the T2DM group were higher than those in the non-T2DM group (P<0.05). SUV_mean, SUV_max, MTV, and TLG were negatively correlated with the efficacy (P<0.05). SUV_mean, SUV_max, MTV combined with TLG predict the highest value of T2DM unrelief. The combined detection of SUV_mean, SUV_max, MTV, and TLG with ¹⁸F-FDG PET/CT technology can evaluate the effect of T2DM on the efficacy of PD-L1 targeted therapy in patients with advanced colorectal cancer, and can objectively and quantitatively predict the patient’s response to treatment.

Key words: ¹⁸F-fluorodeoxyglucose positron emission computed tomography/computed tomography (¹⁸F-FDG PET/CT) technology, type 2 diabetes (T2DM), advanced colorectal cancer, programmed death-ligand 1 (PD-L1) targeted therapy, curative effect

ZHANG Xiaojie, LI Na, YANG Fang, HOU Qianqian, LI Lingling, CAI Hongxu. The Value of ¹⁸F-FDG PET/CT Technology in Evaluating the Effect of T2DM on the Efficacy of PD-L1 Targeted Therapy in Patients with Advanced Colorectal Cancer[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(2): 237-242.

References

[1] 韩子翰, 陈佳佳, 冯楠, 等. 2型糖尿病合并结直肠癌的临床病理特征[J]. 中华胃肠外科杂志, 2019, 22(10):966-971.
[2] André T, Shiu K K, Kim T W, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. The New England Journal of Medicine, 2020, 383(23):2207-2218.
[3] Le D T, Kim T W, van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer:KEYNOTE-164[J]. Journal of Clinical Oncology, 2020, 38(1):11-19.
[4] Kleiner S, Weber W. Stellenwert der FDG-PET/computer tomographie beim kolorektalen karzinom[importance of FDG-PET/computed tomography in colorectal cancer[J]. Radiologe, 2019, 59(9):812-819.
[5] Rodríguez-Fraile M, Cózar-Santiago M P, Sabaté-Llobera A, et al. FDG PET/CT in colorectal cancer[J]. Revista Española De Medicina Nuclear e Imagen Molecular, 2020, 39(1):57-66.
[6] 国家卫生计生委医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017年版)[J]. 中华胃肠外科杂志, 2018, 21(1):92-106.
[7] 张萍, 艾斌. 实体瘤免疫治疗疗效评价标准[J]. 国际肿瘤学杂志, 2016, 43(11):848-851.
[8] Amin M N, Hussain M S, Sarwar M S, et al. How the association between obesity and inflammation may lead to insulin resistance and cancer[J]. Diabetology & Metabolic Syndrome, 2019, 13(2):1213-1224.
[9] Cheng H C, Chang T K, Su W C, et al. Narrative review of the influence of diabetes mellitus and hyperglycemia on colorectal cancer risk and oncological outcomes[J]. Translational Oncology, 2021, 14(7):101089.
[10] Yoon J H, Lee J M, Chang W, et al. Initial M staging of rectal cancer:FDG PET/MRI with a hepatocyte-specific contrast agent versus contrast-enhanced CT[J]. Radiology, 2020, 294(2):310-319.
[11] Chulroek T, Kordbacheh H, Wangcharoenrung D, et al. Comparative accuracy of qualitative and quantitative ¹⁸F-FDG PET/CT analysis in detection of lymph node metastasis from anal cancer[J]. Abdominal Radiology, 2019, 44(3):828-835.
[12] Hasbek Z, Ozer H, Erturk S A, et al. Relationships between hypoxia induced factor-1α and ¹⁸F-FDG PET/CT parameters in colorectal cancer[J]. Revista Española De Medicina Nuclear E Imagen Molecular, 2019, 38(6):355-361.
[13] Yang Z G, Liu Z Y. The efficacy of ¹⁸F-FDG PET/CT-based diagnostic model in the diagnosis of colorectal cancer regional lymph node metastasis[J]. Saudi Journal of Biological Sciences, 2020, 27(3):805-811.
[14] Giannini V, Mazzetti S, Bertotto I, et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with ¹⁸F-FDG PET and MRI radiomics features[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46(4):878-888.
[15] Bashir U, Weeks A, Goda J S, et al. Measurement of ¹⁸F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model[J]. Nuclear Medicine Communications, 2019, 40(6):611-617.

The Value of ¹⁸F-FDG PET/CT Technology in Evaluating the Effect of T2DM on the Efficacy of PD-L1 Targeted Therapy in Patients with Advanced Colorectal Cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	LU Mengyan, FENG Guoyang, GUO Longjun, WANG Juan, LI Chang. The Diagnostic Value of CT Examination Parameters in Lumbar Spinal Stenosis and the Correlation Analysis with Curative Effect and Improvement of Lumbar Function [J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2021, 39(2): 251-256.
[2]	ZHOU Jie, HU Chunfeng. Study on CTP Evaluation of Pathological Parameters of Lung Cancer and the Clinical Efficacy Before and After Radiotherapy and Chemotherapy [J]. Imaging Science and Photochemistry, 2020, 38(5): 822-827.
[3]	LIU Yongxin, LI Linlin, MA Jing. Comparative Study of Whole Body Diffusion Weighted Imaging and CT in Evaluating the Efficacy of Chemotherapy for Lymphoma [J]. Imaging Science and Photochemistry, 2020, 38(5): 929-933.